Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Amgen on Thursday said its just-launched biosimilar of Johnson & Johnson’s autoimmune drug Stelara recorded $150 million in sales in the first quarter, spotlighting rising revenue from the ...

Drugmaker Amgen on Tuesday launched a biosimilar to the widely-prescribed Humira, giving consumers an alternative to the world's top-selling rheumatoid arthritis drug. The new drug, Amjevita ...

Jan 31 (Reuters) - Amgen Inc (AMGN.O), opens new tab said on Tuesday it launched a biosimilar version of AbbVie Inc's (ABBV.N), opens new tab big selling arthritis treatment, the first such ...

Amgen’s biosimilar called Amjevita could provide cost savings to countless patients. Amjevita could generate $900 million in annual revenue for the drugmaker. The stock is a no-brainer buy for ...

Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited discounts for its biosimilar version of Humira — the world’s best-selling medicine — and ...

Amgen will be allowed to sell its Stelara biosimilar “no later than Jan. 1, 2025.” Whether the development with ustekinumab will lead to cost savings and increased access remains to be seen.

Amgen is now down nearly 20% since last November as money continues to rotate from defensive sectors into tech. The biopharma company should benefit from the rapid emergence of biosimilars thanks ...

Biosimilars saved the healthcare system $21 billion over the past six years, according to a recent Amgen report. Nearly 40 biosimilars received regulatory approval over that period, with 22 products ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all ...